Objective To observe the clinical curative effects of edaravone combined with alprostadil in treating unstable angina pectoris. Methods 90 cases of patients with unstable angina pectoris were randomly divided into contrast group and observation group with each group 45 cases. Patients in the contrast group were given conventional custody and conventional drug therapy, while patients in the observation group were given edaravone combined with alprostadil intravenous drip treatment based on the treatment that contrast group conducted. Patients in both groups were given continuous treatment for 2 weeks. Observe and compare the clinical curative effects as well as the serum hsCRP level of before treatment, 7d after treatment and 14d after treatment. 1 month after discharging hospital, all the patients were given 24h dynamic ECG. Compare the frequency of transient ischemia attack, total ischemia time and total load time of myocardial ischemia between both groups. Results The total effective rate in the observation group was significantly higher than the contrast group(P<0.05). 7d and 14d after treatment, the serum hs-CRP levels in the observation group were respectively significantly decreased than the contrast group(P<0.05).1 month after discharging hospital, the frequency of transient ischemia attack, total ischemia time and total load time of myocardial ischemia in the observation group were all significantly decreased than the contrast group(P<0.05). Conclusion Edaravone combined with alprostadil is proved to be effective in treating unstable angina pectoris, which helps to decrease the serum hs-CRP level, improve the myocardial ischemia condition and increase the total effective rate. Thus, it deserves to be widely promoted in clinical field.